Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Attention Deficit Hyperactivity Disorder (ADHD) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including 4P-Pharma SAS, Altus Formulation Inc, Amarantus Bioscience Holdings Inc, APeT Holding BV, Arbor Pharmaceuticals LLC and others.
A Significant contribution to the Attention Deficit Hyperactivity Disorder (ADHD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Attention Deficit Hyperactivity Disorder (ADHD) pipeline included 39 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Attention Deficit Hyperactivity Disorder (ADHD) condition and increased access to investments is encouraging growth of Attention Deficit Hyperactivity Disorder (ADHD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Attention Deficit Hyperactivity Disorder (ADHD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Attention Deficit Hyperactivity Disorder (ADHD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Attention Deficit Hyperactivity Disorder (ADHD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Attention Deficit Hyperactivity Disorder (ADHD). Further, orphan drug status, fast track designation, grants awarded and other special status for Attention Deficit Hyperactivity Disorder (ADHD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Attention Deficit Hyperactivity Disorder (ADHD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Attention Deficit Hyperactivity Disorder (ADHD) Pipeline candidates-
A Significant contribution to the Attention Deficit Hyperactivity Disorder (ADHD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Attention Deficit Hyperactivity Disorder (ADHD) pipeline included 39 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Attention Deficit Hyperactivity Disorder (ADHD) condition and increased access to investments is encouraging growth of Attention Deficit Hyperactivity Disorder (ADHD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Attention Deficit Hyperactivity Disorder (ADHD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Attention Deficit Hyperactivity Disorder (ADHD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Attention Deficit Hyperactivity Disorder (ADHD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Attention Deficit Hyperactivity Disorder (ADHD). Further, orphan drug status, fast track designation, grants awarded and other special status for Attention Deficit Hyperactivity Disorder (ADHD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Attention Deficit Hyperactivity Disorder (ADHD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Attention Deficit Hyperactivity Disorder (ADHD) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Attention Deficit Hyperactivity Disorder (ADHD) drugs
- Late phase: Phase 3 and in-approval Attention Deficit Hyperactivity Disorder (ADHD) drugs
- Company overview
- Snapshot
- Attention Deficit Hyperactivity Disorder (ADHD) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Attention Deficit Hyperactivity Disorder (ADHD)- Disease Overview
2.2 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Snapshot
2.3 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Phase
2.4 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Company
2.5 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 4P-Pharma SAS Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.2 Altus Formulation Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.3 Amarantus Bioscience Holdings Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.4 APeT Holding BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.5 Arbor Pharmaceuticals LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.6 Avekshan LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.7 BCWorld Pharm Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.8 BioHealthonomics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.9 Bionomics Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.10 Cannabis Science Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.11 Cennerv Pharma (S) Pte Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.12 Cingulate Therapeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.13 Collegium Pharmaceutical Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.14 Curemark LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.15 DURECT Corp Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.16 EncepHeal Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.17 Ensysce Biosciences Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.18 Highland Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.19 INVENT Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.20 KemPharm Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.21 leon-nanodrugs GmbH Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.22 Limoxifen BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.23 NLS Pharma Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.24 Otsuka Pharmaceutical Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.25 P2D Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.26 RespireRx Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.27 Reviva Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.28 Seropeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.29 Shenox Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.30 Shionogi & Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.31 SK Biopharmaceuticals Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.32 Sosei Heptares Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.33 Sunovion Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.34 Supernus Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.35 Taho Pharmaceuticals Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.36 Taisho Pharmaceutical Holdings Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.37 Takeda Pharmaceutical Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.38 Tris Pharma Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.39 Vallon Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Drug Details
4.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Drug Overview
4.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Drug Details
5.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Drug Overview
5.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Details
6.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Overview
6.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Details
7.2 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Overview
7.3 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Attention Deficit Hyperactivity Disorder (ADHD)- Disease Overview
2.2 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Snapshot
2.3 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Phase
2.4 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Company
2.5 Attention Deficit Hyperactivity Disorder (ADHD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 4P-Pharma SAS Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.2 Altus Formulation Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.3 Amarantus Bioscience Holdings Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.4 APeT Holding BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.5 Arbor Pharmaceuticals LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.6 Avekshan LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.7 BCWorld Pharm Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.8 BioHealthonomics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.9 Bionomics Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.10 Cannabis Science Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.11 Cennerv Pharma (S) Pte Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.12 Cingulate Therapeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.13 Collegium Pharmaceutical Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.14 Curemark LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.15 DURECT Corp Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.16 EncepHeal Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.17 Ensysce Biosciences Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.18 Highland Therapeutics Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.19 INVENT Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.20 KemPharm Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.21 leon-nanodrugs GmbH Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.22 Limoxifen BV Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.23 NLS Pharma Group Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.24 Otsuka Pharmaceutical Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.25 P2D Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.26 RespireRx Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.27 Reviva Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.28 Seropeutics LLC Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.29 Shenox Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.30 Shionogi & Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.31 SK Biopharmaceuticals Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.32 Sosei Heptares Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.33 Sunovion Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.34 Supernus Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.35 Taho Pharmaceuticals Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.36 Taisho Pharmaceutical Holdings Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.37 Takeda Pharmaceutical Co Ltd Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.38 Tris Pharma Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
3.39 Vallon Pharmaceuticals Inc Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Drug Details
4.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Drug Overview
4.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Drug Details
5.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Drug Overview
5.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Details
6.2 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Overview
6.3 Attention Deficit Hyperactivity Disorder (ADHD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Details
7.2 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Overview
7.3 Attention Deficit Hyperactivity Disorder (ADHD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
